The Medicare Payment Advisory Commission (MedPAC) convened a session to vote on the draft recommendations to lower Medicare spending on Part B drugs. MedPAC staff presented the policy options the Commission is considering as alternative approaches for Medicare to address high prices and uncertain clinical evidence for Part B accelerated approval drugs, lack of price competition for drugs with similar… (Colocho, April 13, 2023) #Drug Pricing